Were Analysts Bullish Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) This Week?

January 16, 2018 - By Linda Rogers

 Were Analysts Bullish Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) This Week?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Coverage

Among 5 analysts covering Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals Inc had 11 analyst reports since June 30, 2016 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, October 23. As per Friday, August 11, the company rating was maintained by Cantor Fitzgerald. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has “Speculative Buy” rating given on Wednesday, September 13 by Canaccord Genuity. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has “Buy” rating given on Friday, December 30 by H.C. Wainwright. Canaccord Genuity maintained Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) rating on Tuesday, October 24. Canaccord Genuity has “Buy” rating and $10.5 target. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 30. The rating was maintained by Cantor Fitzgerald on Monday, June 5 with “Buy”. Cantor Fitzgerald initiated the shares of AUPH in report on Tuesday, April 11 with “Overweight” rating. As per Monday, October 23, the company rating was maintained by Leerink Swann. Below is a list of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) latest ratings and price target changes.

30/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12.0
24/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.5 Maintain
23/10/2017 Broker: Leerink Swann Rating: Outperform Old Target: $10 New Target: $14 Maintain
23/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $14.0 Maintain
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $10 Initiates Coverage On
13/09/2017 Broker: Canaccord Genuity Old Rating: Buy New Rating: Speculative Buy Downgrade
11/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $14.0000 Maintain

The stock increased 0.84% or $0.045 during the last trading session, reaching $5.395. About 557,408 shares traded. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has risen 200.00% since January 16, 2017 and is uptrending. It has outperformed by 183.30% the S&P500.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $446.37 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

More important recent Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) news were published by: Businesswire.com which released: “Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace …” on January 04, 2018, also Fool.com published article titled: “Is Aurinia Pharmaceuticals a Buy?”, Fool.com published: “Here’s What Knocked Aurinia Pharmaceuticals Inc. Down 16.1% in December” on January 05, 2018. More interesting news about Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) was released by: Fool.com and their article: “3 Stocks Wall Street Hasn’t Heard of Yet” with publication date: January 03, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.